

ANITA R. HOTCHKISS, ESQ., [NJ Attorney ID #018491975]  
JENNIFER L. FLETCHER, ESQ., [NJ Attorney ID #914032012]

**GOLDBERG SEGALLA LLP**

301 Carnegie Center, Suite 200  
Princeton, New Jersey 08540

**Mailing address: PO Box 580, Buffalo, NY 14201**

(609) 986-1350

(609) 986-1301 (fax)

Attorneys for Defendants Actavis Pharma, Inc.  
and Actavis LLC f/k/a Actavis Inc.

**FILED**

**DEC 11 2019**

**Judge James F. Hyland**

SANDRA LAURIANO,

*Plaintiff,*

v.

SANOFI S.A.;  
AVENTIS PHARMA S.A.;  
SANOFI U.S. SERVICES INC.,  
formerly known as SANOFI-AVENTIS  
U.S. INC.;  
SANOFI-AVENTIS U.S.  
LLC, separately and doing business as  
WINTHROP U.S.;  
SANDOZ, INC.;  
HOSPIRA, INC.;  
HOSPIRA WORLDWIDE, LLC  
formerly known as HOSPIRA  
WORLDWIDE, INC.; ACCORD  
HEALTHCARE, INC.;  
SUN PHARMA GLOBAL FZE;  
SUN PHARMACEUTICAL  
INDUSTRIES, INC. formerly known as  
CARACO PHARMACEUTICAL  
LABORATORIES, LTD.;  
ACTAVIS LLC formerly known as  
ACTAVIS INC.;  
ACTAVIS PHARMA, INC.;  
AND  
JOHN DOE DRUG COMPANY  
DEFENDANTS #1-10,

*Defendants.*

SUPERIOR COURT OF NEW JERSEY LAW  
DIVISION – MIDDLESEX COUNTY

CASE TYPE: MCL NO. 628

MASTER DOCKET NO.: MID-L-4998-18-CM

DOCKET NO.: **MID-L-6289-19-CM**

**CIVIL ACTION**

**ORDER**

This matter having been opened to the Court on application of Goldberg Segalla LLP, attorneys for Defendants, Actavis Pharma, Inc., Actavis LLC f/k/a Actavis Inc., and Sagent Pharmaceuticals, Inc., for an Order admitting Jennifer Snyder Heis, Esq., *pro hac vice*, and the Court having considered the matter and having found that her firm, Ulmer & Berne LLP, has been long-standing national counsel for Actavis Pharma, Inc., Actavis LLC f/k/a Actavis Inc. and Sagent Pharmaceuticals, Inc., and that this matter involves an area of law in which Ms. Heis specializes, and good cause appearing,

IT IS, on this 11<sup>th</sup> day of December, 2019,

**ORDERED**, that Ms. Heis is admitted *pro hac vice* to represent Defendants, Actavis Pharma, Inc., Actavis LLC f/k/a Actavis Inc. and Sagent Pharmaceuticals, Inc., in this litigation in association with New Jersey counsel Goldberg Segalla LLP, in the above matter; and

**IT IS FURTHER ORDERED** that:

1. Ms. Heis may try the action, but shall not be designated trial counsel under Rule 4:25-4. No proceedings shall be adjourned because Ms. Heis is unavailable;
2. All pleadings, motions, and correspondence to the Court must be submitted by New Jersey counsel, unless the Court specifically waives this provision;
3. Ms. Heis must be accompanied by a member of the New Jersey Bar at all proceedings;
4. Ms. Heis shall consent to the appointment of the Clerk of the Supreme Court of New Jersey as an agent upon whom service of process may be made for all actions against her firm that may arise out of her participation in this matter;


5. Ms. Heis shall be required to make annual payments to the Disciplinary Oversight Committee (Rule 1:201(b)), the New Jersey Lawyers' Fund for Client Protection (Rule 1:28-2(a)), and the New Jersey Lawyers Assistance Program (Rule 1:28B-1(e)).

6. Ms. Heis must, within ten (10) days of the entry of the Order for Admission, pay the fees required by Rule 1:20-1(b), Rule 1:28-2, and Rule 1:28B-1(e), and submit an affidavit of compliance within fifteen (15) days thereafter. During the pendency of these matters, Ms. Heis shall continue to comply with Rule 1:20-1(b), Rule 1:28-2, and Rule 1:28B-1(e) on an annual basis and shall submit an affidavit of compliance within thirty (30) days of such compliance;

7. Admission *pro hac vice* shall be automatically terminated for failure to make any required annual payment, upon appropriate notification from the Administrative Office of the Courts that the annual payment has not been made. Proof of such payment, after filing proof of the initial payment, shall be made no later than February 1st of each year;

8. Noncompliance with any of the requirements of *pro hac vice* admission shall constitute grounds for removal.

**IT IS FURTHER ORDERED** that counsel for Defendants, Actavis Pharma, Inc., Actavis LLC f/k/a Actavis Inc. and Sagent Pharmaceuticals, Inc., shall serve a copy of this Order on all parties within seven (7) days.

  
\_\_\_\_\_  
Hon. James F. Hyland, J. S.C.

Dated :